Corcept Therapeutics
CORT
$113.98
+2.11%
Corcept Therapeutics Inc. is a commercial-stage pharmaceutical company focused on developing and marketing drugs that modulate the effects of cortisol to treat severe metabolic, oncologic, and neuropsychiatric disorders. Its lead product, Korlym (mifepristone), is approved for Cushing's syndrome, and the company is advancing a pipeline including relacorilant and dazucorilant for various cancers and other conditions. Corcept is a niche player in the selective cortisol modulation space, with a strong commercial foothold in Cushing's syndrome and a promising oncology pipeline. The current investor narrative centers on the FDA approval of its new cancer drug Lifyorli in March 2026, which has driven a massive re-rating of the stock, alongside growing optimism about pipeline catalysts and revenue growth.…
CORT
Corcept Therapeutics
$113.98
Related headlines
Investment Opinion: Should I buy CORT Today?
Based on the analysis, I rate Corcept as a Hold. The stock has strong momentum and a promising pipeline, but the current valuation already reflects much of the optimism. The average analyst target of $141.00 implies a 26.3% upside, but the wide range and limited coverage suggest high uncertainty. The thesis is that Lifyorli's approval is a genuine catalyst, but its commercial success is not yet proven, and the core business is decelerating.
Sign up to view all
CORT 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Corcept has a promising pipeline and a strong balance sheet, but the decelerating revenue growth and recent net loss temper enthusiasm. The valuation is not excessive, but the stock has already rallied significantly, and the wide analyst target range indicates uncertainty. The stance would upgrade to bullish if Lifyorli sales exceed expectations and revenue growth re-accelerates, or downgrade to bearish if pipeline setbacks occur or the company's cash burn accelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corcept Therapeutics's 12-month outlook, with a consensus price target around $141.00 and implied upside of +23.7% versus the current price.
Average Target
$141.00
0 analysts
Implied Upside
+23.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$50 - $165
Analyst target range
Analyst coverage is limited, with only 5 analysts providing ratings, and the consensus recommendation is 'none' due to a lack of clear buy/sell consensus. The average target price is $141.00, implying an upside of 26.3% from the current price of $111.62. The target range is wide, from a low of $50.00 to a high of $165.00, indicating high uncertainty about the company's future prospects. The high target of $165 suggests that some analysts expect continued success from Lifyorli and other pipeline drugs, while the low target of $50 reflects concerns about competition or clinical setbacks. Recent ratings actions have been mostly positive, with upgrades from UBS (Neutral to Buy) and Wolfe Research (Underperform to Peer Perform), but the small number of analysts and wide target spread highlight the speculative nature of the stock.
Drowning in data?
Find the real signal!
Bulls vs Bears: CORT Investment Factors
Corcept presents a classic high-risk, high-reward biotech investment. The bull case is anchored by the FDA approval of Lifyorli, which has the potential to transform the company's growth trajectory, supported by a pristine balance sheet and high gross margins. However, the bear case highlights decelerating revenue growth, a recent net loss, and a valuation that already prices in significant success. The most important tension is whether Lifyorli can deliver the blockbuster sales that justify the current market cap of $12.3 billion, or whether the deceleration in the core business and high R&D spending will lead to continued losses. Currently, the bull case has stronger evidence given the positive analyst targets and the transformative potential of the new drug, but the risk is substantial.
Bullish
- FDA approval of Lifyorli drives massive re-rating: The FDA approval of Lifyorli in March 2026 for cancer treatment has transformed Corcept's growth narrative, evidenced by the stock surging from $33.99 on March 9 to $111.62 by September 4, a 228% gain. This approval expands the commercial pipeline beyond Korlym and opens a potentially large oncology market, justifying the market's optimism.
- High gross margin of 98.3%: Corcept maintains an exceptionally high gross margin of 98.3%, reflecting the low cost of goods for its pharmaceutical products. This provides a strong foundation for profitability once operating expenses stabilize, as seen in Q4 2025 when net income was $24.3 million on revenue of $202.1 million.
- Strong balance sheet with minimal debt: The company has a debt-to-equity ratio of just 0.009 and a current ratio of 2.92, indicating ample liquidity and conservative leverage. With $110 million in cash, Corcept is well-positioned to fund its clinical trials and commercial expansion without financial distress.
- Positive analyst sentiment and target upside: Despite limited coverage, the average analyst target price is $141.00, implying a 26.3% upside from the current price of $111.62. Recent upgrades from UBS (Neutral to Buy) and Wolfe Research (Underperform to Peer Perform) suggest improving sentiment among analysts.
Bearish
- Revenue growth decelerating sharply: Q1 2026 revenue growth was only 4.9% year-over-year, down from 28% in Q2 2025 and 14% in Q3 2025. This deceleration suggests that the core Korlym franchise is maturing, and the market's high expectations for Lifyorli may not be met quickly enough.
- Net loss and negative free cash flow in Q1 2026: Corcept reported a net loss of $31.2 million and negative free cash flow of -$17.0 million in Q1 2026, driven by a surge in operating expenses to $211.6 million. This indicates that the company is investing heavily in R&D and commercialization, which could pressure near-term profitability.
- High valuation with negative PEG ratio: The forward PE of 25.35x and PS ratio of 4.75x are elevated, and the PEG ratio is negative (-1.24) due to negative earnings growth expectations. This suggests the stock is priced for perfection, leaving little room for disappointment.
- Limited analyst coverage and wide target range: Only 5 analysts cover the stock, and the target price range is extremely wide, from $50 to $165. This reflects high uncertainty about the company's future, and the lack of a consensus recommendation ('none') indicates that even analysts are divided on the stock's prospects.
CORT Technical Analysis
Corcept's stock has been in a powerful uptrend over the past year, with a 1-year price change of +60.9% and a 6-month change of +229.6%, far outpacing the S&P 500's 18.65% 1-year gain. The current price of $111.62 sits near the upper end of its 52-week range, at approximately 88% of the distance from the low of $28.66 to the high of $126.38, indicating strong momentum but also potential overextension. The stock has more than tripled from its 52-week low, reflecting a sustained bullish trend driven by fundamental catalysts.
Beta
0.45
0.45x market volatility
Max Drawdown
-64.4%
Largest decline past year
52-Week Range
$29-$126
Price range past year
Annual Return
+60.0%
Cumulative gain past year
| Period | CORT Return | S&P 500 |
|---|---|---|
| 1m | +2.9% | -0.9% |
| 3m | +45.9% | +5.6% |
| 6m | +251.9% | +15.0% |
| 1y | +60.0% | +18.1% |
| ytd | +198.4% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CORT Fundamental Analysis
Revenue growth has been solid but decelerating, with Q1 2026 revenue of $164.9 million, up 4.9% year-over-year, compared to 28% growth in Q2 2025 and 14% in Q3 2025. The company's gross margin remains exceptionally high at 98.3%, reflecting the low cost of goods for its pharmaceutical products. However, profitability turned negative in Q1 2026, with a net loss of $31.2 million and an EPS of -$0.30, due to a significant increase in operating expenses, particularly R&D and SG&A, which totaled $211.6 million. The company's balance sheet is conservatively leveraged, with a debt-to-equity ratio of just 0.009 and a current ratio of 2.92, indicating ample liquidity. Free cash flow was negative in Q1 2026 at -$17.0 million, but the company has generated positive FCF in prior quarters, and its cash position of $110 million provides a buffer for ongoing clinical trials.
Quarterly Revenue
$164903000.0B
2026-03
Revenue YoY Growth
+4.9%
YoY Comparison
Gross Margin
98.3%
Latest Quarter
Free Cash Flow
$119788000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CORT Overvalued?
Given the negative trailing net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 4.75x, which is lower than the historical average of around 20x, reflecting the market's expectation of significant future revenue growth. The forward PE of 25.35x suggests that analysts expect earnings to rebound strongly, implying a market that is pricing in a return to profitability. Compared to the industry average PS ratio of 4.75x, Corcept trades at a premium, but this is justified by its high gross margins and potential for pipeline-driven growth. Historically, the stock's PS ratio has ranged from 18x to 75x over the past two years, and the current level is near the lower end, suggesting that the market is not fully pricing in the potential of its oncology pipeline.
PE
36.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 18x~56x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
51.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. Corcept's revenue growth has slowed to just 4.9% year-over-year in Q1 2026, down from 28% in Q2 2025, indicating that the core Korlym franchise is maturing. The company reported a net loss of $31.2 million in Q1 2026, with operating expenses of $211.6 million, reflecting heavy investment in R&D and SG&A. While the balance sheet is conservatively leveraged (debt-to-equity of 0.009) and cash stands at $110 million, the negative free cash flow of -$17.0 million in Q1 2026 could become a concern if the company continues to burn cash without achieving profitability. The high gross margin of 98.3% provides some cushion, but the company's reliance on continued revenue growth to justify its valuation is a key risk.
FAQ
The key risks are financial, competitive, and regulatory. Financially, the company reported a net loss of $31.2 million in Q1 2026 and negative free cash flow, which could persist if operating expenses remain high. Competitively, Lifyorli faces potential competition from other cancer therapies, and the core Korlym franchise is decelerating (4.9% YoY growth). Regulatory risks include clinical trial failures or safety issues that could derail the pipeline. The stock's high valuation (forward PE of 25.35x) leaves little room for disappointment. The most severe risk is a -74% decline to the 52-week low of $28.66 if Lifyorli fails.
The 12-month forecast is uncertain, with three scenarios. The bull case (30% probability) targets $141-$165, driven by strong Lifyorli sales and pipeline progress. The base case (45% probability) targets $111-$141, assuming Lifyorli meets expectations but the core business decelerates. The bear case (25% probability) targets $50-$111, if Lifyorli disappoints or pipeline setbacks occur. The most likely scenario is the base case, with the stock trading near the analyst average of $141, implying a 26.3% upside. The key assumption is that Lifyorli contributes to growth without major setbacks.
Corcept trades at a forward PE of 25.35x and a PS ratio of 4.75x, which is below its historical average of around 20x, suggesting the market is not fully pricing in the pipeline potential. Compared to the industry average PS ratio of 4.75x, Corcept is in line, but its high gross margin of 98.3% justifies a premium. The valuation implies the market expects significant future revenue growth, but the negative PEG ratio (-1.24) indicates that near-term earnings are expected to decline. Overall, the stock appears fairly valued relative to its growth prospects, but the high uncertainty warrants caution.
Corcept offers a compelling risk/reward for investors willing to accept high volatility. The average analyst target of $141 implies a 26.3% upside, but the wide range ($50 to $165) underscores the uncertainty. The stock is not a good buy for conservative investors due to the recent net loss and decelerating revenue growth. However, for those with a high risk tolerance and a long-term view, the FDA approval of Lifyorli and the pipeline potential make it an attractive speculative buy. The biggest downside risk is a -55% decline to the analyst low of $50 if Lifyorli disappoints.
Corcept is more suitable for long-term investment due to its high volatility (beta of 0.446) and the time required for pipeline catalysts to materialize. The stock has a beta of 0.446, indicating lower correlation to the market, but its 229.6% six-month gain suggests high volatility. The company does not pay a dividend, so returns depend on capital appreciation. Given the early stage of Lifyorli and the pipeline, a minimum holding period of 3-5 years is recommended to allow the drugs to reach their full commercial potential. Short-term trading is possible but risky due to the wide analyst target range and potential for sharp pullbacks.
